IL18 and cancer: Extracellular ATP from cancer cells that undergo ICD mediates immune system chemotaxis by binding to purinergic receptor P2Y2 (P2RY2), and promoting the secretion of interleukin 1 β (IL-1β) and interleukin-18 (IL-18) by activating inflammatory corpuscles (Kepp et al., 2021).